Results 81 to 90 of about 148,764 (203)

Impact of Thiazides and Fluoropyrimidines Interaction on Myelotoxicity and Other Adverse Events in Real‐World Practice: A Retrospective Cohort Study

Cancer Medicine, Volume 15, Issue 3, March 2026.
ABSTRACT Introduction The European Summary of Product Characteristics (SmPC) for 5‐FU warns of significant granulocyte decline when combined with thiazides, cyclophosphamide, or methotrexate, based on a 1981 cohort of 14 patients. Despite limited evidence, drug‐interaction checkers still flag this risk.
Gerard Ronda‐Roca, José Porcel‐Maleno, Mónica Lobo‐Palomar, Gustavo Centeno‐Soto, Ana Ruiz‐Casado, Belén Ruiz‐Antorán   +5 more
wiley   +1 more source

Uptake of DPYD and UGT1A1 testing in Italy and adherence to pharmacogenetic guidelines: A 5‐year perspective from an EQA provider

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 445-456, February 2026.
Aims Pharmacogenetic implementation requires awareness of the state‐of‐the‐art practice of laboratories providing pharmacogenetic testing. This study investigated how pharmacogenetic guidelines and recommendations have been implemented over time by Italian laboratories participating in the external quality assessment (EQA) Pharmaco‐scheme established ...
Rossana Roncato, Samantha Perfler, Diletta Pasin, Elena Peruzzi, Michael Woodcock, Henry Thomas, Rebecca Goodall, Simon J. Patton, Erika Cecchin   +8 more
wiley   +1 more source

5FU and oxaliplatin-containing chemotherapy in two dihydropyrimidine dehydrogenase-deficient patients

, 2004
Patients with a germline mutation leading to a deficiency of the dihydropyrimidine dehydrogenase (DPD) enzyme are at risk from developing severe toxicity on the administration of 5FU-containing chemotherapy.
Hospers, GAP, Szabo, BG, Reerink, O, Mulder, NH   +3 more
core   +2 more sources

Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD

Genome Medicine
Background The Alpe-DPD study (NCT02324452) demonstrated that prospective genotyping and dose-individualization using four alleles in DPYD (DPYD*2A/rs3918290, c.1236G > A/rs75017182, c.2846A > T/rs67376798 and c.1679 T > G/rs56038477) can mitigate the ...
Jonathan E. Knikman, Qinglian Zhai, Carin A. T. C. Lunenburg, Linda M. Henricks, Stefan Böhringer, Maaike van der Lee, Femke M. de Man, Steven M. Offer, Shikshya Shrestha, Geert-Jan Creemers, Arnold Baars, Vincent O. Dezentjé, Alexander L. T. Imholz, Frank J. F. Jeurissen, Johanna E. A. Portielje, Rob L. H. Jansen, Paul Hamberg, Helga J. Droogendijk, Miriam Koopman, Peter Nieboer, Marlène H. W. van de Poel, Caroline M. P. W. Mandigers, Ron H. N. van Schaik, Hans Gelderblom, Ron H. J. Mathijssen, Jan H. M. Schellens, Annemieke Cats, Henk-Jan Guchelaar, Jesse J. Swen   +28 more
doaj   +1 more source

Biocatalytic Construction of a Chemical Exchange Saturation Transfer Magnetic Resonance Imaging Nucleoside Probe: Synthesis and Evaluation of 5‐Methyl‐5,6‐Dihydrothymidine

Advanced Synthesis &Catalysis, Volume 368, Issue 1, January 2026.
Al‐Hilfi et al. present a biocatalytic strategy for synthesizing 5‐methyl‐5,6‐dihydrothymidine (5‐MDHT), a sensitive MRI contrast agent. The study demonstrates that recombinant enzyme catalysis offers an efficient, sustainable, and eco‐friendly alternative to traditional chemical synthesis for producing clinically relevant imaging probes.
Aimen Al‐Hilfi, E. Alejandro Castellanos Franco, Connor J. Grady, Zinia Mohanta, Michael T. McMahon, Milana Bazayeva, Zhen Li, Kenneth M. Merz Jr., Assaf A. Gilad   +8 more
wiley   +1 more source

Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity. [PDF]

, 2015
We investigated the clinical relevance of dihydropyrimidine dehydrogenase gene (DPYD) variants to predict severe early-onset fluoropyrimidine (FP) toxicity, in particular of a recently discovered haplotype hapB3 and a linked deep intronic splice site ...
Markus Joerger, Stefan Aebi, Joerger, Markus, Tanja K. Froehlich, Fröhlich, Tanja, Carlo R. Largiadèr, Amstutz, Ursula, Largiadèr, Carlo Rodolfo, Aebi, Stefan, Ursula Amstutz   +9 more
core   +1 more source

DPYD genotype-guided dose personalisation for fluoropyrimidine-based chemotherapy prescribing in solid organ cancer patients in Australia: GeneScreen 5-FU study protocol

BMC Cancer
Background Fluoropyrimidine (FP) chemotherapies are commonly prescribed for upper and lower gastrointestinal, breast and head and neck malignancies. Over 16,000 people with cancer require FP chemotherapies per annum in Australia.
Cassandra White, Hannah Wardill, Christine Paul, Timothy Price, Christos Karapetis, Mark Nalder, Matthew E. Burge, Ann Thomas, Chris Oldmeadow, Daniel Barker, Laura C. Edney, Janet Coller, Joanne Bowen, Cheri Ostroff, Bruce Cheek, Mel Carlson, Trumaine Rankmore, Adnan Nagrial, Stephen Clarke, Lorraine Chantrill, Stephen Ackland, Rodney J. Scott   +21 more
doaj   +1 more source

Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil

, 2001
Dihydropyrimidine dehydrogenase catalyzes the first step in pyrimidine degradation: the NADPH-dependent reduction of uracil and thymine to the corresponding 5,6-dihydropyrimidines. Its controlled inhibition has become an adjunct target for cancer therapy,
Schneider, G, Schnackerz, K D, Lindqvist, Y, Dobritzsch, Doreen,   +3 more
core   +1 more source

The Frequency of DPYD c.557A>G in the Dominican Population and Its Association with African Ancestry

Pharmaceutics
Background/Objectives: Genetic polymorphism of the dihydropyrimidine dehydrogenase gene (DPYD) is responsible for the variability found in the metabolism of fluoropyrimidines such as 5-fluorouracil (5-FU), capecitabine, or tegafur.
Mariela Guevara, Carla González de la Cruz, Fernanda Rodrigues-Soares, Ernesto Rodríguez, Caíque Manóchio, Eva Peñas-Lledó, Pedro Dorado, Adrián LLerena   +7 more
doaj   +1 more source

Characterization of a Rare Nonpathogenic Sequence Variant (c.1905C>T) of the Dihydropyrimidine Dehydrogenase Gene ()

The International Journal of Biological Markers, 2017
Background In the era of precision medicine, the suitability of fluoropyrimidine therapies in clinical oncology can be checked by pharmacogenetic investigations of single patients, thus optimizing resources and indicating the appropriate drugs to ...
Raffaele Palmirotta, Domenica Lovero, Erica Silvestris, Claudia Carella, Claudia Felici, Davide Quaresmini, Paola Cafforio, Franco Silvestris   +7 more
doaj   +1 more source